Roche’s Phase III Actemra RADIATE (RheumAtoiD ArthritIs Study in Anti-TNF FailurEs) trial met its primary endpoint in patients with moderate to severe rheumatoid arthritis (RA) who failed to respond to anti-tumor necrosis factor treatments (anti-TNFs). The third multinational Phase III study of Actemra showed that more patients treated with Actemra plus methotrexate achieved a significant reduction in the signs and symptoms of RA as evaluated by ACR20 following 24 weeks of treatment, ...